Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.

ABSTRACT: Bacterial L-asparaginase has been a universal component of therapies for childhood acute lymphoblastic leukemia since the 1970s. Two principal enzymes derived from Escherichia coli and Erwinia chrysanthemi are the only options clinically approved to date. We recently reported a study of recombinant L-asparaginase (AnsA) from Rhizobium etli and described an increasing type of AnsA family members. Sequence analysis revealed four conserved motifs with notable differences with respect to the conserved regions of amino acid sequences of type I and type II L-asparaginases, particularly in comparison with therapeutic enzymes from E. coli and E. chrysanthemi. These differences suggested a distinct immunological specificity. Here, we report an in silico analysis that revealed immunogenic determinan

SUBMITTER: Huerta-Saquero A 

PROVIDER: S-EPMC3566018 | biostudies-literature | 2013 Jan-Feb

REPOSITORIES: biostudies-literature